BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Phase 3 study of ULTOMIRIS™ (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, met its ...

Objective— Complement activation has been suggested to play a role in atherogenesis. To study the regulation of complement activation in human coronary atherosclerotic lesions, we examined the spatial ...

This is a preview. Log in through your library . Abstract The complement fixation tests with cocto-antigens prepared from virulent mouse spleens or preferably Rivers-Li tissue cultures of the virus ...